Advertisement

Molecular Medicine

, Volume 21, Issue 1, pp 1038–1046 | Cite as

The Prognostic Value of Microsatellite Instability, KRAS, BRAF and PIK3CA Mutations in Stage II Colon Cancer Patients

  • F. Jeroen Vogelaar
  • Felice N. van Erning
  • Marlies S. Reimers
  • Hans van der Linden
  • Hans Pruijt
  • Adriaan J. C. van den Brule
  • Koop Bosscha
Research Article

Abstract

In the era of personalized cancer medicine, identifying mutations within patient tumors plays an important role in defining high-risk stage II colon cancer patients. The prognostic role of BRAF V600E mutation, microsatellite instability (MSI) status, KRAS mutation and PIK3CA mutation in stage II colon cancer patients is not settled. We retrospectively analyzed 186 patients with stage II colon cancer who underwent an oncological resection but were not treated with adjuvant chemotherapy. KRAS mutations, PIK3CA mutation, V600E BRAF mutation and MSI status were determined. Survival analyses were performed. Mutations were found in the patients with each mutation in the following percentages: 23% (MSI), 35% (KRAS), 19% (BRAF) and 11% (PIK3CA). A trend toward worse overall survival (OS) was seen in patients with an MSI (5-year OS 74% versus 82%, adjusted hazard ratio [HR] 1.8, 95% confidence interval [CI] 0.6–4.9) and a KRAS-mutated tumor (5-year OS 77% versus 82%, adjusted HR 1.7, 95% CI 0.8–3.5). MSI and BRAF-mutated tumors tended to correlate with poorer disease-free survival (DFS) (5-year DFS 60% versus 78%, adjusted HR 1.6, 95% CI 0.5–2.1 and 5-year DFS 57% versus 77%, adjusted HR 1.1, 95% CI 0.4–2.6 respectively). In stage II colon cancer patients not treated with adjuvant chemotherapy, BRAF mutation and MSI status both tended to have a negative prognostic effect on disease-free survival. KRAS and MSI status also tended to be correlated with worse overall survival.

Notes

Acknowledgments

The authors wish to thank W Voogd and I de Vrije for excellent technical support performing the mutation analyses.

References

  1. 1.
    O’Connell JB, Maggard MA, Ko CY. (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J. Natl. Cancer Inst. 96:1420–5.CrossRefGoogle Scholar
  2. 2.
    Colussi D, Brandi G, Bazzoli F, Ricciardiello L. (2013) Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. Int. J. Mol. Sci 14:16365–85.Google Scholar
  3. 3.
    Zoratto F, et al. (2014) Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis. Tumour Biol. 35:6195–206.CrossRefGoogle Scholar
  4. 4.
    Davies H, et al. (2002) Mutations of the BRAF gene in human cancer. Nature. 417:949–54.CrossRefGoogle Scholar
  5. 5.
    Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. (2008) BRAF(E600) in benign and malignant human tumours. Oncogene. 27:877–95.CrossRefGoogle Scholar
  6. 6.
    Farina-Sarasqueta A, et al. (2010) The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann. Oncol. 21:2396–402.CrossRefGoogle Scholar
  7. 7.
    Ogino S, et al. (2009) CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 58:90–6.CrossRefGoogle Scholar
  8. 8.
    Roth AD, et al. (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol. 28:466–74.CrossRefGoogle Scholar
  9. 9.
    Yokota T, et al. (2011) BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br. J. Cancer 104:856–62.CrossRefGoogle Scholar
  10. 10.
    De RW, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol. 11:753–62.CrossRefGoogle Scholar
  11. 11.
    Souglakos J, et al. (2009) Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer. Br. J. Cancer 101:465–72.CrossRefGoogle Scholar
  12. 12.
    Reimers MS, Zeestraten EC, Kuppen PJ, Liefers GJ, van de Velde CJ. (2013) Biomarkers in precision therapy in colorectal cancer. Gastroenterol. Rep. (Oxf). 1:166–83.CrossRefGoogle Scholar
  13. 13.
    Lochhead P, et al. (2013) Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J. Natl. Cancer Inst. 105:1151–6.CrossRefGoogle Scholar
  14. 14.
    Funkhouser WK Jr, et al. (2012) Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. J. Mol. Diagn. 14:91–103.CrossRefGoogle Scholar
  15. 15.
    Samuels Y, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science. 304:554.CrossRefGoogle Scholar
  16. 16.
    Ogino S, et al. (2009) PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J. Clin. Oncol. 27:1477–84.CrossRefGoogle Scholar
  17. 17.
    Forbes SA, et al. (2011) COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39:D945–50.CrossRefGoogle Scholar
  18. 18.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373–83.CrossRefGoogle Scholar
  19. 19.
    Van Leersum NJ, et al. (2013) Increasing prevalence of comorbidity in patients with colorectal cancer in the South of the Netherlands 1995–2010. Int. J. Cancer 132:2157–63.CrossRefGoogle Scholar
  20. 20.
    Heideman DA, et al. (2009) A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes. Cell. Oncol. 31:329–33.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Hoang JM, Cottu PH, Thuille B, Salmon RJ, Thomas G, Hamelin R. (1997) BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res. 57:300–3.PubMedGoogle Scholar
  22. 22.
    Zhou XP, et al. (1998) Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer. 21:101–7.CrossRefGoogle Scholar
  23. 23.
    Donada M, Bonin S, Barbazza R, Pettirosso D, Stanta G. (2013) Management of stage II colon cancer — the use of molecular biomarkers for adjuvant therapy decision. BMC Gastroenterol. 13:36.CrossRefGoogle Scholar
  24. 24.
    Lin CC, et al. (2014) The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer. J. Surg. Oncol. 110:451–7.CrossRefGoogle Scholar
  25. 25.
    Nash GM, et al. (2010) KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer. Ann. Surg. Oncol. 17:416–24.CrossRefGoogle Scholar
  26. 26.
    Kim GP, et al. (2007) Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J. Clin. Oncol. 25:767–72.CrossRefGoogle Scholar
  27. 27.
    Xiao H, et al. (2013) Poorly differentiated colorectal cancers: correlation of microsatellite instability with clinicopathologic features and survival. Am. J. Clin. Pathol. 140:341–7.CrossRefGoogle Scholar
  28. 28.
    Safaee AG, Jafarnejad SM, Tan L, Saeedi A, Li G. (2012) The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis. PLoS One. 7:e47054.CrossRefGoogle Scholar
  29. 29.
    Ogino S, et al. (2009) KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin. Cancer Res. 15:7322–9.CrossRefGoogle Scholar
  30. 30.
    Imamura Y, et al. (2012) Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin. Cancer Res. 18:4753–63.CrossRefGoogle Scholar
  31. 31.
    Cathomas G. (2014) PIK3CA in Colorectal Cancer. Front. Oncol. 4:35.CrossRefGoogle Scholar
  32. 32.
    Day FL, et al. (2013) PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin. Cancer Res. 19:3285–96.CrossRefGoogle Scholar
  33. 33.
    Farina SA, et al. (2011) PIK3CA kinase domain mutation identifies a subgroup of stage III colon cancer patients with poor prognosis. Cell. Oncol. (Dordr). 34:523–31.CrossRefGoogle Scholar
  34. 34.
    Berg M, et al. (2013) Influence of microsatellite instability and KRAS and BRAF mutations on lymph node harvest in stage I-III colon cancers. Mol. Med. 19:286–93.CrossRefGoogle Scholar
  35. 35.
    Berg M, et al. (2015) Molecular subtypes in stage II-III colon cancer defined by genomic instability: early recurrence-risk associated with a high copy-number variation and loss of RUNX3 and CDKN2A. PLoS One. 10:e0122391.CrossRefGoogle Scholar
  36. 36.
    Febbo PG, et al. (2011) NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology. J. Natl. Compr. Canc. Netw. 9 Suppl 5:S1–32.; quiz S33.CrossRefGoogle Scholar
  37. 37.
    Galon J, et al. (2014) Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J. Pathol. 232:199–209.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2015

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • F. Jeroen Vogelaar
    • 1
    • 2
  • Felice N. van Erning
    • 3
    • 4
  • Marlies S. Reimers
    • 5
  • Hans van der Linden
    • 6
  • Hans Pruijt
    • 7
  • Adriaan J. C. van den Brule
    • 6
  • Koop Bosscha
    • 1
  1. 1.Department of SurgeryJeroen Bosch Hospital’s HertogenboschThe Netherlands
  2. 2.Department of SurgeryVieCuri Medical CenterVenrayThe Netherlands
  3. 3.Department of ResearchNetherlands Comprehensive Cancer Organisation (IKNL)EindhovenThe Netherlands
  4. 4.Department of Public HealthErasmus MC University Medical CentreRotterdamThe Netherlands
  5. 5.Department of SurgeryLeiden University Medical CenterLeidenThe Netherlands
  6. 6.Department of PathologyJeroen Bosch HospitalHertogenboschThe Netherlands
  7. 7.Department of Internal MedicineJeroen Bosch HospitalHertogenboschThe Netherlands

Personalised recommendations